Cholecystokinin is not a major determinant for the changes in beta-cell function seen after pancreatico-biliary diversion in rats
- PMID: 1841824
Cholecystokinin is not a major determinant for the changes in beta-cell function seen after pancreatico-biliary diversion in rats
Abstract
The influence of longterm increase in the plasma CCK levels on beta-cell function in rats was studied by using the pancreatico-biliary diversion (PBD) model. An intravenous glucose load (800 mg glucose/kg) was performed three weeks after the PBD operation. Additionally a group of PBD operated animals as well as an unoperated group received the CCK receptor antagonist L364,718 continuously during the three week study period. The proliferation rate of endocrine pancreatic cells was studied by means of 3H-thymidine administration. PBD caused a decrease in basal levels of insulin and glucose and an augmented insulin secretory response after glucose injection. There was no appreciable influence on the glucose elimination rate. When PBD animals were given the CCK receptor antagonist no differences were observed with regard to insulin and glucose compared to PBD animals without antagonist. The CCK-antagonist did not influence the beta-cell function in unoperated animals. Further, the proliferation rate of the endocrine pancreatic cells was not significantly changed in the PBD rats. The results suggest that PBD is accompanied by significant changes in basal and stimulated insulin secretion. These changes are probably not a direct consequence of the increased plasma CCK levels that follows PBD. Moreover, the insulin secretory response to glucose in normal rats was not influenced by longterm administration of the CCK receptor antagonist. Our observations should encourage further studies on the complex entero-insular interactions following pancreaticobiliary diversion.
Similar articles
-
The changes in the rat parotid glands following total parenteral nutrition and pancreatico-biliary diversion are not mediated by cholecystokinin.Int J Pancreatol. 1996 Oct;20(2):109-18. doi: 10.1007/BF02825509. Int J Pancreatol. 1996. PMID: 8968866
-
Physiological role of cholecystokinin in meal-induced insulin secretion in conscious rats. Studies with L 364718, a specific inhibitor of CCK-receptor binding.Diabetes. 1987 Oct;36(10):1212-5. doi: 10.2337/diab.36.10.1212. Diabetes. 1987. PMID: 3308589
-
Regulation of pancreatic endocrine function by cholecystokinin: studies with MK-329, a nonpeptide cholecystokinin receptor antagonist.J Clin Endocrinol Metab. 1990 May;70(5):1312-8. doi: 10.1210/jcem-70-5-1312. J Clin Endocrinol Metab. 1990. PMID: 2186058 Clinical Trial.
-
Cholecystokinin in the entero-insular axis.Diabetes Res Clin Pract. 1989;7 Suppl 1:S79-85. doi: 10.1016/0168-8227(89)90092-2. Diabetes Res Clin Pract. 1989. PMID: 2680370 Review.
-
Cholecystokinin and the regulation of insulin secretion.Scand J Gastroenterol. 1992;27(3):161-5. doi: 10.3109/00365529208999942. Scand J Gastroenterol. 1992. PMID: 1502476 Review. No abstract available.
Cited by
-
Pancreatic beta-cells: from generation to regeneration.Semin Cell Dev Biol. 2010 Oct;21(8):838-44. doi: 10.1016/j.semcdb.2010.07.007. Epub 2010 Aug 3. Semin Cell Dev Biol. 2010. PMID: 20688184 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical